Methotrexate and risk of Lung disease in Rheumatoid Arthritis: A nationwide population-based cohort study from Denmark

S. Burhan Shaker (Copenhagen, Denmark), E. Ibfelt (Copenhagen, Denmark), R. Jacobsen (Copenhagen, Denmark), T. Kopp (Copenhagen, Denmark), R. Cordtz (Aalborg, Denmark), A. Jakobsen (Copenhagen, Denmark), N. Seersholm (Copenhagen, Denmark), L. Dreyer (Aalborg, Denmark)

Source: Virtual Congress 2020 – What is new in interstitial lung diseases of known origin?
Session: What is new in interstitial lung diseases of known origin?
Session type: Oral Presentation
Number: 4574
Disease area: Interstitial lung diseases

Congress or journal article abstractWebcastSlide presentationE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
S. Burhan Shaker (Copenhagen, Denmark), E. Ibfelt (Copenhagen, Denmark), R. Jacobsen (Copenhagen, Denmark), T. Kopp (Copenhagen, Denmark), R. Cordtz (Aalborg, Denmark), A. Jakobsen (Copenhagen, Denmark), N. Seersholm (Copenhagen, Denmark), L. Dreyer (Aalborg, Denmark). Methotrexate and risk of Lung disease in Rheumatoid Arthritis: A nationwide population-based cohort study from Denmark. 4574

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: